Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shalaka, Agarkhedkar"'
Autor:
Sanjay K. Lalwani, Sharad Agarkhedkar, Balasubramanian Sundaram, Niranjana S. Mahantashetti, Nandini Malshe, Shalaka Agarkhedkar, Olivier Van Der Meeren, Shailesh Mehta, Naveen Karkada, Htay Htay Han, Narcisa Mesaros
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 1, Pp 120-127 (2017)
Multivalent combination vaccines have reduced the number of injections and therefore improved vaccine acceptance, timeliness of administration and global coverage. The hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovir
Externí odkaz:
https://doaj.org/article/74df3590d8e14f68b1dcac7fc7378524
Autor:
Rajesh Joshi, Neeta Hanumante, Uma Nayak, Shalaka Agarkhedkar, Paresh Thakkar, Jayesh Sanmukhani, Ravindra Mittal
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 12, Iss 1, Pp SC09-SC13 (2018)
Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as
Externí odkaz:
https://doaj.org/article/8ea10934717b44a8878d720300e2792f
Autor:
Sanjay Lalwani, Sharad Agarkhedkar, Nithya Gogtay, Sonali Palkar, Shalaka Agarkhedkar, Urmila Thatte, Hoshang Vakil, Rekha Jonnalagedda, Paola Pedotti, Margaret Hoyle, Chiranjiwi Bhusal, Ashwani Arora
Publikováno v:
International Journal of Infectious Diseases, Vol 38, Iss C, Pp 36-42 (2015)
Background: This phase 3, multi-center, open-label study evaluated the immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, Menveo®; Novartis Vaccines and Diagnostics S.r.l., Siena, Italy) in healthy Indian subje
Externí odkaz:
https://doaj.org/article/e7357cfc23ef48bab6a6f72f15d4309b
Autor:
Natacha Le Dren-Narayanin, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma, Krishnamurthy Balasundaram, Sharad Agarkhedkar, Shalaka Agarkhedkar, Vani Sundaraiyer, Mark Cutler, Christine Juergens
Publikováno v:
Pediatric Infectious Disease Journal. 36:e283-e285
In an open-label study in India, 200 healthy participants 6-17 years of age received 13-valent pneumococcal conjugate vaccine (PCV13). PCV13 elicited robust functional antibody immune responses. No adverse events were reported by caregivers at the 1-
Autor:
Shailesh Mehta, Sanjay Lalwani, Shalaka Agarkhedkar, Balasubramanian Sundaram, Narcisa Mesaros, Naveen Karkada, Sharad Agarkhedkar, Htay Htay Han, Nandini Malshe, Olivier Van Der Meeren, Niranjana S Mahantashetti
Publikováno v:
Human Vaccines & Immunotherapeutics
Multivalent combination vaccines have reduced the number of injections and therefore improved vaccine acceptance, timeliness of administration and global coverage. The hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovir
Autor:
Ravindra Mittal, Jayesh Sanmukhani, Neeta Hanumante, Uma Siddhartha Nayak, Paresh Thakkar, Rajesh Joshi, Shalaka Agarkhedkar
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 12, Iss 1, Pp SC09-SC13 (2018)
Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as
Autor:
Stephen, Cape, Amol, Chaudhari, Vivek, Vaidya, Ravindra, Mulay, Shalaka, Agarkhedkar, Charles, Shermer, Marcus, Collins, Raydel, Anderson, Sharad, Agarkhedkar, Prasad S, Kulkarni, Scott, Winston, Robert, Sievers, Rajeev M, Dhere, Bhagwat, Gunale, Ken, Powell, Paul A, Rota, Mark, Papania
Publikováno v:
Vaccine. 32:6791-6797
Background Measles is a highly infectious respiratory disease which causes 122,000 deaths annually. Although measles vaccine is extremely safe and effective, vaccine coverage could be improved by a vaccine that is more easily administered and transpo
Autor:
Margaret Hoyle, Ashwani Kumar Arora, Shalaka Agarkhedkar, Paola Pedotti, Sanjay Lalwani, Urmila M Thatte, Sonali Palkar, Chiranjiwi Bhusal, Hoshang Vakil, Sharad Agarkhedkar, Nithya J Gogtay, Rekha Jonnalagedda
Publikováno v:
International Journal of Infectious Diseases, Vol 38, Iss C, Pp 36-42 (2015)
Summary Background This phase 3, multi-center, open-label study evaluated the immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, Menveo ® ; Novartis Vaccines and Diagnostics S.r.l., Siena, Italy) in healthy Ind
Autor:
BJ Mahendra, DH Ashwath Narayana, Sharad Agarkhedkar, HS Ravish, BR Harish, Shalaka Agarkhedkar, SN Madhusudana, Ashwin Belludi, Khaleel Ahmed, Rekha Jonnalagedda, Hoshang Vakil, Chiranjiwi Bhusal, Ashwani Kumar Arora
Despite availability of effective rabies vaccines, India has the highest global mortality rate for rabies. Low socio-economic communities are most affected due to lack of awareness of the disease and poor compliance to post-exposure prophylactic regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6413a3d061fc07e72edb538e57b13860
https://europepmc.org/articles/PMC4514298/
https://europepmc.org/articles/PMC4514298/
Autor:
Somnath Mangrule, Sonali Palkar, Prasad S. Kulkarni, Sameer Jog, Varsha Parulekar, Sanjay Lalwani, Sharad Agarkhedkar, Shalaka Agarkhedkar, Sidram K. Raut, Ashish Bavdekar
Publikováno v:
Human vaccinesimmunotherapeutics. 10(3)
A live attenuated influenza A(H1N1)pdm 2009 vaccine was developed and distributed in India in 2010. We estimated the vaccine effectiveness (VE) against laboratory-confirmed pandemic H1N1 (pH1N1) infections in patients with influenza-like illness who